Skip to main content

Tofacitinib and Malignancy Risk: Dr. Seoyoung Kim

Dr. David Liew interviews Dr. Seoyoung Kim at the ACR21 annual meeting.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×